Clinical Trials Directory

Trials / Conditions / Thrombocythemia, Essential

Thrombocythemia, Essential

11 registered clinical trials studyying Thrombocythemia, Essential — 3 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic M
NCT07518940
Carmen FavaN/A
RecruitingMPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People
NCT07362225
MPN Research Foundation—
RecruitingA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631
Merck Sharp & Dohme LLCPhase 3
CompletedAn Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-72
NCT05223920
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Phase 2
Active Not RecruitingHematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
NCT04081220
The University of Texas Health Science Center at San AntonioPhase 2
CompletedProspective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essen
NCT03212053
Hospices Civils de LyonN/A
CompletedTreatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
NCT02912884
Dr Yan Beauverd—
UnknownMyeloproliferative Neoplasms and Bone Structure
NCT01816022
University of Southern Denmark—
CompletedA Study in Myeloproliferative Disorders
NCT01134120
Eli Lilly and CompanyPhase 1
TerminatedA Safety Study of XL019 in Adults With Myelofibrosis
NCT00522574
ExelixisPhase 1
CompletedSafety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compar
NCT00567502
Shire—